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Recent studies suggest that the commonly prescribed anti-osteoporosis drugs bis-
phosphonates (BPs) might also exhibit antitumor activity. We investigated a possible 
anticancer effect of BPs on B-chronic lymphocytic leukemia (CLL) cells obtained from 
peripheral blood of 26 CLL patients. 
Zoledronate, etidronate and clodronate were administered in vitro simultaneous-
ly to following activation stimuli: i) CD40L-expressing fibroblasts, ii) soluble recom-
binant CD40L produced in our laboratory +IL-4, iii) CpG ODN 2006+IL-15 with or 
without bone marrow stromal cells (BMSC). CLL cell viability, activation/prolifera-
tion were monitored by flow cytometry.
We unexpectedly observed that BPs generated a protective effect from spontane-
ous apoptosis in 11/26 (42%) patients (viability + 18%-392%) and an augmentation in 
CLL cell activation/proliferation in 61% of the samples (S+G2M phase: +100%±25). 
Interestingly, protection from spontaneous apoptosis or increment of cell activation, 
required the presence of either fibroblasts, BMSC or autologous Nurse Like Cells 
(NLC). 
We thus hypothesized that supportive cells are involved in the BPs effects either 
through cell-cell interactions with leukemic cells or T cells, or through soluble factors 
release in the medium. Functional experiments with transwells suggest that stromal 
cells, in presence of Clodronate, release soluble factors in the medium that may prob-
ably concur to the unexpected Clodronate-mediated enhancement of CLL cell activa-
tion/proliferation.
This work is in progress and several critical questions on the mechanisms are still 
unanswered. Nevertheless, the phenomenological data argue that caution should be 
taken when administering BPs against osteoporosis in elderly persons, who could 
have Monoclonal B Lymphocytosis or CLL. 
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